Marazuela Mónica, Sánchez de Paco Graciano, Jiménez Isabel, Carraro Rafael, Fernández-Herrera Jesús, Pajares José María, Gómez-Pan Antonio
Department of Endocrinology, Hospital Universitario de la Princesa, 28006 Madrid, Spain.
Endocr J. 2002 Jun;49(3):315-8. doi: 10.1507/endocrj.49.315.
A 33-year old female was diagnosed as Graves' disease and started on carbimazole. One month later when she was already euthyroid only on carbimazole therapy, she developed acute pancreatitis associated with mild cholestatic hepatitis and erythema nodosum. Carbimazole therapy was interrupted, pancreatic and liver function gradually improved and became normalized two weeks later. Other potential etiological causes of acute pancreatitis, hepatitis and erythema nodosum were excluded. Rechallenge with a single dose of carbimazole led to a new episode of acute pancreatitis and cholestatic hepatitis one day later. The appearance of different hypersensitivity reactions including pancreatitis, hepatitis and erythema nodosum, together with the observation that the interval between drug intake and onset of symptoms became shorter with repeated exposure to carbimazole, point to an immune-mediated mechanism. Carbimazole has to be added to the list of drugs capable of inducing acute pancreatitis, and should be emphasized the need to discontinue this medication as soon as there is evidence of pancreatic dysfunction.
一名33岁女性被诊断为格雷夫斯病,并开始服用卡比马唑。一个月后,当她仅通过卡比马唑治疗处于甲状腺功能正常状态时,她患上了急性胰腺炎,并伴有轻度胆汁淤积性肝炎和结节性红斑。卡比马唑治疗中断,胰腺和肝功能逐渐改善,两周后恢复正常。排除了急性胰腺炎、肝炎和结节性红斑的其他潜在病因。单剂量卡比马唑再次激发试验导致一天后出现新的急性胰腺炎和胆汁淤积性肝炎发作。包括胰腺炎、肝炎和结节性红斑在内的不同超敏反应的出现,以及观察到随着反复接触卡比马唑,药物摄入与症状发作之间的间隔缩短,提示存在免疫介导机制。卡比马唑必须被列入能够诱发急性胰腺炎的药物清单,并且应该强调一旦有胰腺功能障碍的证据就需要停用这种药物。